Hansa Biopharma AB Company Description

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe.

The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.

It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.

In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation.

It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies.

Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Hansa Biopharma AB (publ)

Country	Sweden
Founded	2007
Industry	Biological Products, Except Diagnostic Substances
Employees	135
CEO	Renee Aguiar-Lucander

Contact Details

Address: ScheelevAegen 22 Lund, 223 63 Sweden
Phone	46 46 16 56 70
Website	hansabiopharma.com

Stock Details

Ticker Symbol	24H
Exchange	Frankfurt Stock Exchange
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	SEK
SIC Code	2836

Key Executives

Name	Position
Renee Aguiar-Lucander	Chief Executive Officer
C. Ballantyne	Chief Financial Officer
Monika Tornsen	Chief Operating Officer
Klaus Sindahl	Head of Investor Relations